GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (NAS:KA) » Definitions » Asset Turnover

Kineta (Kineta) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Kineta Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Kineta's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Kineta's Total Assets for the quarter that ended in Mar. 2024 was $6.36 Mil. Therefore, Kineta's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Kineta's annualized ROE % for the quarter that ended in Mar. 2024 was 2,332.78%. It is also linked to ROA % through Du Pont Formula. Kineta's annualized ROA % for the quarter that ended in Mar. 2024 was -644.20%.


Kineta Asset Turnover Historical Data

The historical data trend for Kineta's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Asset Turnover Chart

Kineta Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
0.73 0.66 0.07 0.39

Kineta Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.34 - - -

Competitive Comparison of Kineta's Asset Turnover

For the Biotechnology subindustry, Kineta's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kineta's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Kineta's Asset Turnover falls into.



Kineta Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Kineta's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=5.442/( (17.435+10.281)/ 2 )
=5.442/13.858
=0.39

Kineta's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (10.281+2.433)/ 2 )
=0/6.357
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Kineta  (NAS:KA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Kineta's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-40.952/-1.7555
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-40.952 / 0)*(0 / 6.357)*(6.357/ -1.7555)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-3.6212
=ROA %*Equity Multiplier
=-644.20 %*-3.6212
=2,332.78 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Kineta's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-40.952/6.357
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-40.952 / 0)*(0 / 6.357)
=Net Margin %*Asset Turnover
= %*0
=-644.20 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Kineta Asset Turnover Related Terms

Thank you for viewing the detailed overview of Kineta's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Kineta (Kineta) Business Description

Traded in Other Exchanges
Address
219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.
Executives
Raymond J. Bartoszek director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato director, officer: Chief Executive Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips officer: President C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny officer: General Counsel C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker officer: Chief Financial Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux officer: Chief Scientific Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga officer: See Remarks C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith officer: SVP and General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma officer: EVP, Head of R&D C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky director C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust 10 percent owner C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust 10 percent owner C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109